Radiopharmaceutical for detecting PSMA - positive metastatic colon cancer: Matched-pair comparison of 18F-BF3-Cy3-ACUPA and 68Ga-PSMA PET/MRI

---

Aras O., DEMİRDAĞ Ç., Kommidi H., Ting R., SAYMAN H. B.

NUCLEAR MEDICINE REVIEW, cilt.25, sa.2, ss.129-130, 2022 (ESCI, Scopus)

• Yayın Türü: Makale / Tam Makale
• Cilt numarası: 25 Sayı: 2
• Basım Tarihi: 2022
• Doi Numarası: 10.5603/nmr.a2022.0027
• Dergi Adı: NUCLEAR MEDICINE REVIEW
• Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, CINAHL, EMBASE, MEDLINE, Directory of Open Access Journals
• Sayfa Sayıları: ss.129-130
• Anahtar Kelimeler: (18) F-BF3-Cy(3-)ACUPA, (68) Ga-PSMA, colorectal cancer, PET, MRI, PSMA
• İstanbul Üniversitesi-Cerrahpaşa Adresli: Evet

Özet

Prostate-specific membrane antigen (PSMA) - based radiopharmaceuticals are promising for the evaluation of PSMA-positive non-prostate cancers. In this case study, 18F-BF3-Cy3-ACUPA and 68Ga-PSMA positron emission tomography/magnetic resonance imaging (PET/MRI) were compared in a patient with metastatic colon cancer. Both 18F-BF3-Cy3-ACUPA and 68Ga-PSMA PET/MRI showed biopsy-proven metastatic left external iliac adenopathy, highlighting the feasibility of PSMA uptake in PET/MRI of metastatic nodal disease from colon cancer. Along with imaging evaluation, PSMA-based radiopharmaceuticals may also be used as a surrogate imaging tracer for potential theranostic applications using alpha or beta emitters in the context of PSMA-directed radiopharmaceutical therapy in advanced and progressive colorectal cancer.